VBI Vaccinea is a biopharmaceutical company developing novel technologies that seek to expand vaccine.
VBI Vaccines is a biopharmaceutical company developing novel technologies that seek to expand vaccine protection in large underserved markets. VBI’s eVLP vaccine platform allows for the design of enveloped virus-like particle vaccines that closely mimic the target virus. VBI is headquartered in Cambridge, MA with research facilities in Ottawa, Canada.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 5, 2016 | Post-IPO Equity | $13.60M | 1 | — | — | Detail |
Jan 4, 2007 | Series A | $35.70M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | — | Post-IPO Equity |